Cover Image
市場調查報告書

腎臟及泌尿科設備市場分析:各類型 (透析,尿結石,輸尿管支架,碎石器,尿失禁及骨盆器官脫垂,薦骨神經調節,陰道網膜及吊帶及其它) 與市場區隔預測

Nephrology And Urology Devices Market Analysis By Type (Dialysis, Urinary Stone, Ureteral Stents, Lithotripters, Urinary Incontinence & Pelvic Organ Prolapse, Sacral Neuromodulation, Vaginal Meshes & Slings, and Others), And Segment Forecasts to 2024

出版商 Grand View Research, Inc. 商品編碼 370437
出版日期 內容資訊 英文 78 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腎臟及泌尿科設備市場分析:各類型 (透析,尿結石,輸尿管支架,碎石器,尿失禁及骨盆器官脫垂,薦骨神經調節,陰道網膜及吊帶及其它) 與市場區隔預測 Nephrology And Urology Devices Market Analysis By Type (Dialysis, Urinary Stone, Ureteral Stents, Lithotripters, Urinary Incontinence & Pelvic Organ Prolapse, Sacral Neuromodulation, Vaginal Meshes & Slings, and Others), And Segment Forecasts to 2024
出版日期: 2016年08月09日 內容資訊: 英文 78 Pages
簡介

本報告提供全球腎臟及泌尿科設備置市場相關調查,彙整市場各類型,各地區別趨勢,今後預測,及加入此市場的主要企業簡介等資料。

第1章 調查方法與調查範圍

第2章 摘要整理

第3章 市場概要

第4章 市場變數,趨勢,範圍

  • 市場區隔和範圍
  • 推動市場的要素分析
  • 阻礙市場的要素分析
  • 滲透與成長預測製圖
  • 競爭環境
  • 因素別SWOT分析
  • 產業分析:波特五力分析

第5章 市場分類1:各類型預測與趨勢分析

  • 類型變動分析
  • 透析
  • 尿結石
  • 尿失禁及骨盆器官脫垂
  • 良性攝護腺肥大症

第6章 市場分類2:各地區預測與趨勢分析:類型,各終端用戶

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第7章 競爭環境

  • 策略性架構
  • 市場進入分類
  • 企業簡介
    • 旭化成株式會社
  • B.Braun Group
  • Baxter International, Inc
  • Boston Scientific Corporation
  • C.R. Bard, Inc
  • Coloplast AS
  • Cook Medical
  • Dornier MedTech
  • Fresenius Medical Care AG & Co. KGaA
  • 日機裝株式會社
  • Nipro株式會社
  • NxStage Medical, Inc.
  • Olympus Corporation Medical Systems株式會社
  • Rockwell Medical Technologies, Inc.
  • Terumo Corporation
  • Svenska Cellulosa Aktiebolaget (SCA)
  • ONTEX International N.V.
  • Kimberly-Clark Corporation
  • First Quality Enterprises, Inc.
  • Teleflex Incorporated
  • Siemens Healthineers
  • Medtronic
  • Medline Industries, Inc.
  • STORZ Medical AG

圖表

目錄
Product Code: GVR-1-68038-090-3

The global nephrology and urology devices market is expected to reach USD 31.3 billion by 2024, according to a new study by Grand View Research, Inc. The market is driven by technological advancements that are anticipated to serve the market with future growth opportunities. These advancements include inclusion of stem cells, wearable artificial kidneys, combined use of ion-sensitive sensors & electrodes, living membranes, shockwave, and laser lithotripsy.

These technologies serve as efficient methods of renal care, which are capable of improving overall patient health and quality of life. In addition, improved uremic toxin and fluid removal, relatively less hypotension episodes, better control of blood pressure, overall improvement in mineral metabolism, better survival rate, and reduction in hospitalization rates & costs. In addition, these advancements also have a substantial impact on patient's quality of life through increased volume of dialysate, ultrafiltration capacity, and higher solute clearance.

The unprecedented adoption of unhealthy lifestyle has exerted a major impact on the market, leading to high prevalence of chronic diseases, such as cancer and diabetes, which serve as a contributing factor toward developing kidney and urinary diseases. Moreover, the widening of geriatric population base, which is highly susceptible to developing the aforementioned chronic diseases is expected to impel the demand for highly efficient devices.

Furthermore, increasing geographical presence of major market players is expected to raise the levels of awareness pertaining to advanced technologies available for treatment in emerging economies, thus impelling the market growth throughout the forecast period. In addition, increasing participation in research studies to further improve these devices is expected to propel high scale growth for this market during the forecast period.

Further Key Findings from the Study Suggest:

The dialysis devices in the product segment held a dominant share in 2015. This is a consequence of the high clinical urgency to curb the unprecedented growth in renal failure globally. Moreover, easy availability and presence of a wide-scale portfolio in the global market is facilitating a higher penetration of dialysis devices, thus resulting in a higher share

In 2015, Europe dominated the overall nephrology and urology devices market with a share of over 40.0%. The increasing number of product approvals by healthcare organizations and presence of large patient volume requiring dialysis across this region are anticipated to be a contributing factor toward substantial share

Asia Pacific is anticipated to witness at a lucrative CAGR of over 7.0% during the forecast period. This can be attributed to rising per capita healthcare spending and increasing availability of minimally invasive devices & awareness pertaining to the, amongst patient base present across the region

The dominant players are indulging into collaborative strategies and new product development in order to capture a larger share of the market. The increasing number of mergers & acquisitions are believed to strengthen the competitive scenario of nephrology and urology market

For instance, in September 2013, Baxter International, Inc. acquired Gambro AB, a dialysis products manufacturer, to facilitate expansion and enhancement of renal therapy product portfolio, in order to gain a competitive advantage over other players

Table of Contents

Chapter 1: Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2: Executive Summary

Chapter 3: Preimplantation Genetic Diagnosis Industry Outlook

  • 3.1. Market segmentation
  • 3.2. Market size and growth prospects, 2013-2024
  • 3.3. Preimplantation genetic diagnosis market dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Rising incidences of genetic diseases
      • 3.3.1.2. Demand for healthy and successful embryo implantation
      • 3.3.1.3. Increase in rate of infertility
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. Ethical and legal constraints
  • 3.4. Key opportunities prioritized, 2015
  • 3.5. Industry analysis-Porter's
  • 3.6. Preimplantation genetic diagnosis PESTEL Analysis

Chapter 4: Preimplantation Genetic Diagnosis Type Outlook

  • 4.1. Global preimplantation genetic diagnosis revenue share, by type, 2015 & 2024
  • 4.2. PGD for chromosomal abnormalities
    • 4.2.1. PGD for chromosomal abnormalities market, 2013-2024(USD Million)
  • 4.3. PGD for HLA typing
    • 4.3.1. PGD for HLA typing market, 2013-2024(USD Million)
  • 4.4. PGD for X-linked diseases
    • 4.4.1. PGD for X-linked diseases market, 2013-2024(USD Million)
  • 4.5. PGD for gender selection
    • 4.5.1. PGD for gender selection market, 2013-2024(USD Million)
  • 4.6. PGD for Other genetic disorders
    • 4.6.1. PGD for other genetic disorders market, 2013-2024(USD Million)

Chapter 5: Preimplantation Genetic Diagnosis Application Outlook

  • 5.1. Global preimplantation genetic diagnosis revenue share, by application, 2015 & 2024
  • 5.2. Identification of HLA-compatible embryos for stem cell therapy
    • 5.2.1. HLA-compatible embryos for stem cell therapy market, 2013-2024(USD Million)
  • 5.3. Prognosis improvement in in-vitro fertilization patient
    • 5.3.1. IVF prognosis market, 2013-2024(USD Million)
  • 5.4. Late onset genetic disorders
    • 5.4.1. Late onset genetic disorders market, 2013-2024(USD Million)
  • 5.5. Inherited genetic disease
    • 5.5.1. Inherited genetic disease market, 2013-2024(USD Million)
  • 5.6. Others PGD applications
    • 5.6.1. Others PGD applications market, 2013-2024(USD Million)

Chapter 6: Preimplantation Genetic Diagnosis Regional Outlook

  • 6.1. Preimplantation genetic diagnosis revenue share, by region, 2015 & 2024
  • 6.2. North America
    • 6.2.1. North America preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada preimplantation genetic diagnosis market, 2013-2024(USD Million)
  • 6.3. Europe
    • 6.3.1. Europe preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Germany preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.3.3. UK
      • 6.3.3.1. UK preimplantation genetic diagnosis market, 2013-2024(USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.4.3. China
      • 6.4.3.1. China preimplantation genetic diagnosis market, 2013-2024(USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Mexico preimplantation genetic diagnosis market, 2013-2024(USD Million)
  • 6.6. MEA
    • 6.6.1. MEA preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa preimplantation genetic diagnosis market, 2013-2024(USD Million)

Chapter 7: Competitive Landscape

  • 7.1. F. Hoffmann-La Roche AG
    • 7.1.1. Company Overview
    • 7.1.2. Financial Performance
    • 7.1.3. Product Benchmarking
    • 7.1.4. Strategic Initiatives
  • 7.2. Genea
    • 7.2.1. Company Overview
    • 7.2.2. Financial Performance
    • 7.2.3. Product Benchmarking
  • 7.3. Quest Diagnostics
    • 7.3.1. Company Overview
    • 7.3.2. Financial Performance
    • 7.3.3. Product Benchmarking
    • 7.3.4. Strategic Initiatives
  • 7.4. Illumina Inc.
    • 7.4.1. Company Overview
    • 7.4.2. Financial Performance
    • 7.4.3. Product Benchmarking
    • 7.4.4. Strategic Initiatives
  • 7.5. Natera
    • 7.5.1. Company Overview
    • 7.5.2. Financial Performance
    • 7.5.3. Product Benchmarking
    • 7.5.4. Strategic Initiatives
  • 7.6. Genesis Genetics LLC
    • 7.6.1. Company Overview
    • 7.6.2. Financial Performance
    • 7.6.3. Product Benchmarking
  • 7.7. Reprogenetics LLC
    • 7.7.1. Company Overview
    • 7.7.2. Financial Performance
    • 7.7.3. Product Benchmarking
    • 7.7.4. Strategic Initiatives
  • 7.8. Laboratory Corporation of America Holdings(LabCorp)
    • 7.8.1. Company Overview
    • 7.8.2. Financial Performance
    • 7.8.3. Product Benchmarking
    • 7.8.4. Strategic Initiatives
  • 7.9. Reproductive Genetics Institute Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Product Benchmarking
    • 7.9.3. Strategic Initiatives
  • 7.10. California Pacific Medical Center
    • 7.10.1. Company Overview
    • 7.10.2. Financial Performance
    • 7.10.3. Product Benchmarking
    • 7.10.4. Strategic Initiatives

List of Tables

  • TABLE 1: Preimplantation Genetic Diagnosis Market - Industry Snapshot & Key Buying Criteria, 2013 - 2024
  • TABLE 2: Global preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 3: Global preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 4: Preimplantation genetic diagnosis market, by region, 2013 - 2024 (USD Million)
  • TABLE 5: Preimplantation genetic diagnosis- Key market driver analysis
  • TABLE 6: Global incidence rate of genetic disorders
  • TABLE 7: Preimplantation genetic diagnosis - Key market restraint analysis
  • TABLE 8: Risk of aneuploidy with rising maternal age
  • TABLE 9: North America preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 10: North America preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 11: U.S. preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 12: U.S. preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 13: Canada preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 14: Canada preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 15: Europe preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 16: Europe preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 17: Germany preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 18: Germany preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 19: UK preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 20: UK preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 21: Asia Pacific preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 22: Asia Pacific preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 23: Japan preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 24: Japan preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 25: China preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 26: China preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 27: Latin America preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 28: Latin America preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 29: Brazil preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 30: Brazil preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 31: Mexico preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 32: Mexico preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 33: Brazil preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 34: Brazil preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 35: South Africa preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 36: South Africa preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1: Preimplantation genetic diagnosis market segmentation
  • FIG. 2: Global preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 3: Preimplantation genetic diagnosis market dynamics
  • FIG. 4: Abnormality in oocytes with increasing maternal age
  • FIG. 5: Key opportunities prioritized, 2015
  • FIG. 6: Preimplantation genetic diagnosis market Porter's analysis
  • FIG. 7: Preimplantation genetic diagnosis market PESTEL analysis
  • FIG. 8: Preimplantation genetic diagnosis revenue share, by type, 2015 & 2024
  • FIG. 9: PGD for chromosomal abnormalities market , 2013 - 2024 (USD Million)
  • FIG. 10: PGD for HLA typing market , 2013 - 2024 (USD Million)
  • FIG. 11: PGD for X-linked diseases market , 2013 - 2024 (USD Million)
  • FIG. 12: PGD for gender selection market , 2013 - 2024 (USD Million)
  • FIG. 13: PGD for other genetic disorders market , 2013 - 2024 (USD Million)
  • FIG. 14: Preimplantation genetic diagnosis revenue share, by application, 2015 & 2024
  • FIG. 15: HLA-compatible embryos for stem cell therapy market , 2013 - 2024 (USD Million)
  • FIG. 16: IVF prognosis market , 2013 - 2024 (USD Million)
  • FIG. 17: Late onset genetic disorders market , 2013 - 2024 (USD Million)
  • FIG. 18: Inherited genetic disease market , 2013 - 2024 (USD Million)
  • FIG. 19: Others PGD applications market , 2013 - 2024 (USD Million)
  • FIG. 20: Preimplantation genetic diagnosis market share, by region, 2015 & 2024
  • FIG. 21: North America preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 22: U.S. preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 23: Canada preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 24: Europe preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 25: Germany preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 26: UK preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 27: Asia Pacific preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 28: Japan preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 29: China preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 30: Latin America preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 31: Brazil preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 32: Mexico preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 33: MEA preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 34: South Africa preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
Back to Top